Welcome to the dog days of summer. Like much of the country, the temperature is slowly being turned up underneath the 340B pot and it’s downright hot in the kitchen.

Efforts by drug manufacturers and their allies to undermine 340B have created a lot of misunderstanding about the discount drug program.

Good news for 340B? Speaking of which, we’ve had some decidedly good news recently. The biggest was the June 15 Supreme Court decision striking down HHS's...

We put a lot of hard work into our monthly 340Buzz series to share expert insight and important updates with our readers. So it gives us great pleasure to announce that the 340Buzz was named the 2022 Blog of the Year.

We were pleased to engage with attendees and speakers at the National Rural Health Association annual meeting on issues related to both 340B and revenue cycle, at both the state and federal levels.

What happens in Vegas stays in Vegas? Not on this trip! I’m excited to share how specialty pharmacies, manufacturers, payers, and other stakeholders gathered in Sin City to address the business and clinical components of specialty pharmacy.

In May, the gears of justice continued to slowly turn on the various 340B contract pharmacy court appeals.

Things change fast these days in 340B, thanks to the ongoing contract pharmacy exclusions by some 16 drug manufacturers and the ever-evolving rules around submitting claims data.

Can it be that virtual meetings are now a thing of the past? With the best of intentions, in-person meetings in 2022 are back in full force.